340B Drug Pricing Program
In this Leadership Dialogue conversation, Tina Freese Decker, president and CEO of Corewell Health and 2025 AHA board chair, talks with Chad Golder, general counsel for the American Hospital Association (AHA), about the complex legal landscape hospitals and health systems must navigate to ensure…
A U.S. District Court for the District of Columbia judge today ruled against Johnson and Johnson and sided with the Department of Health and Human Services and hospitals in a lawsuit brought by J&J challenging the government’s authority to reject J&J’s proposed 340B rebate model.
A U.S. District Court for the District of Columbia judge June 27 ruled against Johnson & Johnson and sided with the Department of Health and Human Services and hospitals in a lawsuit brought by J&J challenging the government’s authority to reject J&J’s proposed 340B rebate model.
The AHA June 16 released a report showing hospitals that participated in the 340B Drug Pricing Program are not only subject to disproportionately greater oversight by the federal government, but they also significantly outperform drug companies in terms of program compliance.
AHA Post-Acute Care Advocacy Alliance News Update - June 13, 2025
Advocacy is such an important part of what we do as hospitals and health systems — and what the AHA does on behalf of our field — to help ensure that we get the resources we need to care for our communities.
Not only are 340B Drug Pricing Program hospitals subject to disproportionately greater oversight by the federal government, they outperform drug companies in terms of program compliance to a substantial degree. These discrepancies underscore the need for increased federal oversight of drug…
340B Advocacy Alliance Bulletin for June 13, 2025
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs.
The AHA June 4 filed an amicus brief (https://www.aha.org/amicus-brief/2025-06-04-aha-files-brief-defending-tennessees-340b-contract-pharmacy-law) in the U.S. District Court for the Middle District of Tennessee in defense of the state’s 340B contract pharmacy law prohibiting drug companies from…